← boardnext 2026-12next 2029-10
MGTX
MeiraGTx, LLCdistress 1/10 · well-funded / low risk$11.96-2%today-18% from 52w high
Oncology 1
Lead: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract
Revenue
pre-revenue
Liquidity
$78M
Runway
—
Shares 1y
+15%
Price & events
+43.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-3.0%
1W
+1.2%
1M
+28.3%
3M
+47.6%
6M
+40.8%
1Y
+150.6%
2Y
-18.4%
5Y
-23.0%
All
Overview
- Market Cap
- $1.11B
- Volume
- 27.27K
- 52 Week Range
- $6.99 – $14.66
- Total Shares
- 92.61M
- Float Shares
- 52.35M
- Short %
- 7.21%
- % Held by Insiders
- 17.12%
- % Held by Institutions
- 61.57%
- RVOL
- 0.03x
- Beta
- 1.21
Pipeline stages · 3 programs
AAV2-hAQP1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AAV-GAD
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AAV2hAQP1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, AAV2-hAQP1 Concentration 3rmat | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | — | recruiting |
| 2029-10 Estimated 50% readout ~2029-11-15 | Phase 1/2 | AAV-GADrmat | Parkinson's Disease | — | active not recruiting |
| 2032-02 Estimated 50% readout ~2032-03-17 | Phase 2 | AAV2-hAQP1rmat | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | — | enrolling by invitation |
| 2026-07 | Phase 1 | AAV2hAQP1 | Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction | 17 | active not recruiting |
Catalyst news & presentations · 8
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-30partnershipmultiple · Entry into $10M securities purchase agreement and registration rights agreement.SEC 8-K
- April 16, 2026 at 8:00 a.m. ETconferencedata presentationsecondaryPhase 1AAV-hAQP1 · Webcast to present 3-year Phase 1 dataSEC 8-K
- 2026-04-15partnershipRPGR product · Asset purchase of RPGR gene therapy from Janssen for $25M upfront plus milestones and royaltiesSEC 8-K
- 2025-11-07partnershipAAV-AIPL1 · Entered strategic collaboration with Lilly for ophthalmology genetic medicines; upfront $75M and up to $400M in milestones.SEC 8-K
- second calendar quarter of 2025regulatory submissionFiled (NDA/BLA)Closing of collaboration agreements with HologenSEC 8-K
- 2025-06-26partnershipReceived UK FDI clearances for proposed transaction with Hologen LimitedSEC 8-K
- 2025-03-09partnershipStrategic collaboration with Hologen for CNS gene therapies and manufacturing, with $200M upfront and up to $230M additional funding.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $28 (+137% upside) · 8 analysts
- 2026-07-08HC Wainwright & Co.Buy
- 2026-07-08RBC CapitalOutperform
- 2026-05-15RBC CapitalOutperform
- 2026-04-22Piper SandlerOverweight
- 2026-04-17RBC CapitalOutperform
- 2026-04-01Evercore ISI GroupOutperform
Competitors — Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract
- none identified
Recent news
- 2026-07-22Form 144 MEIRAGTX HOLDINGS PLC For: 21 July By Investing.com - Investing.com Australia
- 2026-07-22Form 4 MeiraGTx Holdings PLC For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-22Form 4 MeiraGTx Holdings PLC For: 21 July By Investing.com - Investing.com South Africa
- 2026-07-22MeiraGTx CFO & COO Giroux sells $700,560 in shares By Investing.com - Investing.com Nigeria
- 2026-07-22Form 144 MEIRAGTX HOLDINGS PLC For: 21 July By Investing.com - Investing.com Canada
- 2026-07-22MeiraGTx Holdings (NASDAQ: MGTX) CFO sells 56,000 shares in plan trade - Stock Titan
- 2026-07-15Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High? - Zacks Investment Research
- 2026-07-12What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near - The Motley Fool
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.